We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel POC Coagulometer with Lab-Like Precision to Revolutionize Coagulation Testing

By LabMedica International staff writers
Posted on 20 Sep 2023
Print article
Image: The broad-spectrum POC coagulometer is well-suited for emergency room and emergency vehicle use (Photo courtesy of Perosphere)
Image: The broad-spectrum POC coagulometer is well-suited for emergency room and emergency vehicle use (Photo courtesy of Perosphere)

In emergency settings, when patients arrive with a bleed or require urgent surgery, doctors rely solely on clinical judgment to determine if a patient is adequately anticoagulated for reversal treatment. Until now, there was no point-of-care (POC) diagnostic tool available that could provide immediate insights into a patient's coagulation status, especially for those on direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Now, a novel POC coagulometer offers a real-time, comprehensive view of a patient's clotting status right in the emergency room.

Perosphere Technologies (Danbury, CT, USA) is engaged in the further development and commercialization of a novel POC coagulometer, known as the Perosphere Technologies POC Coagulometer. This device is unique in its ability to promptly and accurately assess clotting times across various types of anticoagulant medications, including DOACs. It requires only 14 microliters of fresh whole blood and yields easy-to-interpret clotting time results with lab-like precision in 3-8 minutes.

This rapid diagnostic capability can significantly influence timely and accurate treatment decisions, setting a new benchmark for emergency care for patients at risk of bleeding. Its compact design and flexibility make it suitable for use not just in emergency departments and ambulances but also across various healthcare settings like hospitals, clinics, surgical centers, physician offices, and pharmacies. While the POC Coagulometer has received the CE Mark for use in the European Union, it is still pending approval in the United States.

“Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results,” said Dr. Stefan Zappe, Principal Investigator and Chief Technology Officer at Perosphere Technologies. “By providing physicians with the tools to make faster, better-informed treatment decisions, our technology has strong potential to significantly enhance patient care.”

Related Links:
Perosphere Technologies 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.